Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    TED13751 | Bakersfield, California, U.S.
Previous Study | Return to List | Next Study

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02187848
Recruitment Status : Active, not recruiting
First Posted : July 11, 2014
Last Update Posted : April 30, 2020
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objectives:

  • To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 2 weeks (with and without a loading dose at Cycle 1) to patients with advanced solid tumors (Main Escalation and Loading Dose Escalation Q2W).
  • To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 3 weeks to patients with advanced solid tumors (Escalation Q3W Cycle).
  • To assess efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (Expansion Phase) when SAR408701 is administered once every 2 weeks with or without a loading dose at Cycle 1.

Secondary Objectives:

  • To characterize the overall safety profile of SAR408701.
  • To characterize the pharmacokinetic (PK) profile of SAR408701 and of its potential circulating derivatives.
  • To identify the recommended phase 2 dose (RP2D) of SAR408701.
  • To assess the potential immunogenicity of SAR408701.

Condition or disease Intervention/treatment Phase
Neoplasm Malignant Drug: SAR408701 Phase 1 Phase 2

Detailed Description:
The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, and at least one follow-up visit after the end-of-treatment visit. Additional follow-up visits may be required until resolution or stabilization of adverse events (at least 30 days). Treatment may continue until precluded by toxicity, progression, or upon patient's request. If the patient stops study treatment for reason other than disease progression, follow-up visit will be performed every 3 months until disease progression or initiation of another anti-tumor treatment or death, whichever comes first.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 313 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors
Actual Study Start Date : July 23, 2014
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: SAR408701 Main Dose Escalation Cohort
Dose escalation administered intravenously, once every two weeks
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort colorectal cancer (CRC)
Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort non-squamous NSCLC
Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort gastric adenocarcinoma
Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Loading Dose Escalation cohorts (Escalation bis)
Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)
Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort colorectal cancer (CRC-L)
Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Expansion Cohort small cell lung cancer (SCLC)
Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Experimental: SAR408701 Dose Escalation every 3 weeks cohort
Dose escalation administered intravenously, once every three weeks
Drug: SAR408701
Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous




Primary Outcome Measures :
  1. Number of dose limiting adverse events (every 2 week cycle) [ Time Frame: 4 weeks ]
  2. Assessment of overall response rate using standard imaging and RECIST 1.1 criteria [ Time Frame: Up to 40 months ]
  3. Number of dose limiting adverse events (every 3 week cycle) [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Number of treatment emergent adverse events [ Time Frame: Up to 4 years ]
  2. Maximum concentration (Cmax) [ Time Frame: 2 months ]
  3. Time to reach maximum concentration (tmax) [ Time Frame: 2 months ]
  4. Trough plasma concentrations (Ctrough) [ Time Frame: Intensive testing within first 2 months, then every 2 weeks ]
  5. Area under the plasma concentration versus time curve between 0 and 14 days (AUC0-14day) for Q2W or between 0 and 21 days (AUC-21 day) for Q3W [ Time Frame: 2 months ]
  6. Mean systemic clearance (CL) [ Time Frame: 2 months ]
  7. Clearance at steady state (CLss) [ Time Frame: 2 months ]
  8. Accumulation ratio (Rac) on AUC0-14day and Cmax [ Time Frame: 2 months ]
  9. Detection of the development of anti-SAR408701 antibody [ Time Frame: Up to 40 months ]
  10. Duration of response [ Time Frame: Up to 40 months - assessment every 6-8 weeks ]
  11. Time to Progression [ Time Frame: Up to 40 months - assessment every 6-8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Locally advanced or metastatic solid malignant tumor disease for which no standard alternative therapy is available.
  • Availability of archived tumor tissue for carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 or CEA) testing.
  • For participants in the Dose Escalation Cohorts (Main Escalation and Loading Dose Cohorts at every 2 week cycle and Dose Escalation every 3 week cycle): patients with tumors expressing or likely to be expressing CEACAM5 which includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC), gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial ovarian cancer and endometrial adenocarcinoma are favored, or if carcinoembryonic antigen (CEA) plasma levels >5 ng/mL.
  • For participants to the Expansion Phase cohorts: patients with CRC or with CEACAM5 positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma (including esophago-gastric junction adenocarcinoma of the Siewert types II and III).
  • At least one measurable lesion by RECIST v1.1 in the Expansion Phase only.
  • At least one lesion amenable to biopsy (Expansion cohort - CRC and gastric cancer only). Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy.
  • Signed informed consent.

Exclusion criteria:

  • Aged less than 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status more than 1.
  • New or progressing brain involvement.
  • Concurrent treatment with any other anticancer therapy or inadequate wash-out period for prior anticancer therapies before first administration of SAR408701, or non-resolution of toxicities induced by these anticancer therapies.
  • Female or male patients with reproductive potential who do not agree to use an accepted effective method of contraception during the study treatment period and for at least 3 months following completion of study treatment.
  • Pregnancy or breast-feeding.
  • Participation to any clinical research study evaluating another investigational drug or therapy within 3 weeks of initiation of study regimen.
  • Prior therapy targeting CEACAM5.
  • Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates).
  • Poor bone marrow reserve resulting in low blood cell counts.
  • Poor kidney and liver functions.
  • Any of the following within 6 months prior to study enrolment: infectious or inflammatory bowel disease, diverticulitis, gastrointestinal perforation, intestinal obstruction, and gastrointestinal hemorrhage. Patients with malabsorption syndrome are excluded.
  • Previous history and or unresolved corneal disorders. The use of contact lenses is not permitted.
  • Unresolved signs and symptoms of neuropathy; Grade 1 is acceptable if prior neurotoxic drugs such as cisplatin or taxanes.
  • Abnormal cardiac function defined by a left ventricular ejection fraction (LVEF) of <50%.
  • Cardiac conduction defects, or any other clinically significant arrhythmias.
  • Known intolerance to infused protein products.
  • Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose reduction cannot be considered.
  • Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before 1st administration of SAR408701.
  • Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid as per package insert of each drug, including the following: increase intraocular pressure, prior or current glaucoma, narrow-angle glaucoma, ongoing eye infection, uncontrolled hypertension, known/suspected allergy to constituents of the preparation (such as sodium bisulfite).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02187848


Locations
Show Show 26 study locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT02187848    
Other Study ID Numbers: TED13751
2014-001130-29 ( EudraCT Number )
First Posted: July 11, 2014    Key Record Dates
Last Update Posted: April 30, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms